These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16953158)

  • 1. Will absorbable metal stent technology change our practice?
    Bosiers M; Deloose K; Verbist J; Peeters P
    J Cardiovasc Surg (Torino); 2006 Aug; 47(4):393-7. PubMed ID: 16953158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promise and challenges of bioabsorbable stents.
    Waksman R
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):407-14. PubMed ID: 17722019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Absorbable coronary stents. New promising technology].
    Erbel R; Böse D; Haude M; Kordish I; Churzidze S; Malyar N; Konorza T; Sack S
    Herz; 2007 Jun; 32(4):308-19. PubMed ID: 17607538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The road to bioabsorbable stents: reaching clinical reality?
    Erne P; Schier M; Resink TJ
    Cardiovasc Intervent Radiol; 2006; 29(1):11-6. PubMed ID: 16195840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on bioabsorbable stents: from bench to clinical.
    Waksman R
    J Interv Cardiol; 2006 Oct; 19(5):414-21. PubMed ID: 17020566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of stent strut design in metallic stents and biodegradable scaffolds.
    Foin N; Lee RD; Torii R; Guitierrez-Chico JL; Mattesini A; Nijjer S; Sen S; Petraco R; Davies JE; Di Mario C; Joner M; Virmani R; Wong P
    Int J Cardiol; 2014 Dec; 177(3):800-8. PubMed ID: 25449502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering aspects of stents design and their translation into clinical practice.
    Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A
    Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The bioresorbable coronary scaffold].
    Hassell ME; van de Hoef TP; Damman P; Delewi R; Serruys PW; Piek JJ
    Ned Tijdschr Geneeskd; 2012; 156(36):A4994. PubMed ID: 22951133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcomes of the titanium-NO stent registry.
    Mosseri M; Tamari I; Plich M; Hasin Y; Brizines M; Frimerman A; Miller H; Jafari J; Guetta V; Solomon M; Lotan C
    Cardiovasc Revasc Med; 2005; 6(1):2-6. PubMed ID: 16263349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP; Ambrose JA; Coppola JT
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.
    Park DW; Park SW; Park KH; Lee BK; Kim YH; Lee CW; Hong MK; Kim JJ; Park SJ
    Am J Cardiol; 2006 Aug; 98(3):352-6. PubMed ID: 16860022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary artery stents: evaluating new designs for contemporary percutaneous intervention.
    Kandzari DE; Tcheng JE; Zidar JP
    Catheter Cardiovasc Interv; 2002 Aug; 56(4):562-76. PubMed ID: 12124974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining stent technologies for femoral interventions.
    Bosiers M; Deloose K; Callaert J; Maene L; Keirse K; Verbist J; Peeters P
    J Cardiovasc Surg (Torino); 2012 Aug; 53(4):465-73. PubMed ID: 22854526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The approach to small vessels in the era of drug-eluting stents.
    Holmes DR; Kereiakes DJ
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S31-7. PubMed ID: 15665796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of in-stent restenosis.
    Bosiers M; Deloose K; Keirs K; Verbist J; Peeters P
    J Cardiovasc Surg (Torino); 2010 Aug; 51(4):591-8. PubMed ID: 20671644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.